Number of the records: 1
Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension
- 1.
SYSNO ASEP 0570226 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension Author(s) Kala, P. (CZ)
Gawrys, O. (CZ)
Miklovič, M. (CZ)
Vaňourková, Z. (CZ)
Škaroupková, P. (CZ)
Jíchová, Š. (CZ)
Sadowski, J. (PL)
Kompanowska - Jezierska, E. (PL)
Walkowska, A. (PL)
Veselka, J. (CZ)
Táborský, M. (CZ)
Maxová, H. (CZ)
Vaněčková, Ivana (FGU-C) RID, ORCID
Červenka, L. (CZ)Number of authors 14 Source Title Journal of Hypertension. - : Lippincott Williams & Wilkins - ISSN 0263-6352
Roč. 41, č. 1 (2023), s. 99-114Number of pages 16 s. Language eng - English Country GB - United Kingdom Keywords endothelin system ; hypertension ; Ren-2 renin transgenic rat ; renin-angiotensin system ; volume-overload heart failure OECD category Cardiac and Cardiovascular systems R&D Projects LX22NPO5104 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) Method of publishing Open access Institutional support FGU-C - RVO:67985823 UT WOS 000921029000013 EID SCOPUS 85143180046 DOI https://doi.org/10.1097/HJH.0000000000003307 Annotation Objective:Evaluation of the effect of endothelin type A (ETA) receptor blockade on the course of volume-overload heart failure in rats with angiotensin II-dependent hypertension.Methods:Ren-2 renin transgenic rats (TGR) were used as a model of hypertension. Heart failure was induced by creating an aorto-caval fistula (ACF). Selective ETA receptor blockade was achieved by atrasentan. For comparison, other rat groups received trandolapril, an angiotensin-converting enzyme inhibitor (ACEi). Animals first underwent ACF creation and 2 weeks later the treatment with atrasentan or trandolapril, alone or combined, was applied, the follow-up period was 20 weeks.Results:Eighteen days after creating ACF, untreated TGR began to die, and none was alive by day 79. Both atrasentan and trandolapril treatment improved the survival rate, ultimately to 56% (18 of 31 animals) and 69% (22 of 32 animals), respectively. Combined ACEi and ETA receptor blockade improved the final survival rate to 52% (17 of 33 animals). The effects of the three treatment regimens on the survival rate did not significantly differ. All three treatment regimens suppressed the development of cardiac hypertrophy and lung congestion, decreased left ventricle (LV) end-diastolic volume and LV end-diastolic pressure, and improved LV systolic contractility in ACF TGR as compared with their untreated counterparts.Conclusion:The treatment with ETA receptor antagonist delays the onset of decompensation of volume-overload heart failure and improves the survival rate in hypertensive TGR with ACF-induced heart failure. However, the addition of ETA receptor blockade did not enhance the beneficial effects beyond those obtained with standard treatment with ACEi alone. Workplace Institute of Physiology Contact Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Year of Publishing 2024 Electronic address https://journals.lww.com/jhypertension/Fulltext/2023/01000/Endothelin_type_A_receptor_blockade_attenuates.11.aspx
Number of the records: 1